drugset / Trial / NCT00499850

Phase I FOLFOX Combination

NCT00499850

Phase 1 Completed 18 enrolled Genzyme, a Sanofi Company
RandomizedSingle-groupOpen-labelTreatment

Summary

A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.

Timeline

Start
2005-08
Primary completion
2006-06
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral
Background Leucovorin Small molecule Intravenous
Background Oxaliplatin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous